1)refractory and relaps acute myelogenous leukemia难治/复发急性髓性白血病
1.Objective To evaluate the efficacy and untoward reaction of FLAG protocol(fludarabine,cytosine arabinoside and granulocyte colony stimulating factor) in treatment of refractory and relaps acute myelogenous leukemia To evaluate the efficacy and untoward reaction.目的探讨FLAG方案[氟达拉滨(Flud)联合阿糖胞苷(Ara-C)和粒细胞集落刺激因子(G-CSF)]治疗难治/复发急性髓性白血病(AML)的临床疗效及不良反应。
英文短句/例句
1.The Efficacy of FLAG Protocol in Treatment of Refractory and Relaps Acute Myelogenous LeukemiaFLAG方案治疗难治/复发急性髓性白血病的疗效观察
2.Comparison of Regimens in Treatment of Refractory and Relapsed Acute Myeloid Leukemia;难治/复发性急性髓系白血病治疗方案比较
3.Priming Regimen for Patients with Refractory or Relapsed Acute Myelogenous Leukemia (in Vivo and in Vitro);预激方案治疗急性难治性、复发性髓性白血病的初步研究（体内、体外）
4.Clinical Investigation of G-CSF Priming Regiment in Treatment of Relapsing, Refractory and Senile Acute Myeloid Leukemia;预激方案治疗难治复发性及老年性急性髓系白血病的临床研究
5.Clinical Observation of FLAG Regimen in Treatment of Refractory or Relapsed Acute Myelogenous LeukemiaFLAG方案治疗难治性复发性急性髓细胞白血病的临床观察
6.Clinical Analysis of FLAG Regimen in the Treatment of Relapsed/refractory Acute Myeloid Leukemia;FLAG方案治疗复发/难治急性髓系白血病的临床病例分析
7.Effects of FLAG Regimen in Treatment Refractory and Relapsed Acute Myeloid Leukemia;FLAG方案治疗难治复发急性髓系白血病的疗效观察
8.Treating Four Refractory and Relapse Acute Myelocytic Leukemia Patients with Sequential Dual Induction Chemotherapy: FA Combined with Priming ChemotherapyFA+CAG序贯双诱导治疗复发难治急性髓系白血病4例
9.Clinical study of preexcitation program containing Amsacrine in the treatment of refractory or relapsed Acute Myeloid Leukemia含安丫啶的预激方案治疗难治/复发急性髓细胞白血病的临床研究
10.IDA-FLAG Regimen in Treatment of Patients with Refractory or Relapsed Acute LeukemiaIDA-FLAG方案治疗复发难治的急性白血病
11.Treatment outcome of FLAG regimen for the refractory and relapsed acute leukemiaFLAG方案治疗难治复发性急性白血病的临床观察
12.The Experimental Research and Clinical Observation on the Treatment of Refractory/relapse Acute Myeloid Leukemia with Topoisomerase Ⅰ Inhibitors Topotecan;拓扑异构酶Ⅰ抑制剂拓扑替康治疗难治/复发性急性髓系白血病的基础与临床研究
13.Clinical Study on Fludarabin Combined with Cytarabine Regimen in the Treatment of Patients with Refractory and Relapsed Acute Myeloid Leukemia氟达拉滨联合阿糖胞苷方案治疗复发及难治性急性髓系白血病的临床研究
14.Efficacy of aclacinomycin plus intermediate dose of cytarabine for patients with refractory and relapsed acute myeloid leukemia阿柔比星联合中剂量阿糖胞苷诱导治疗难治和复发性急性髓样白血病的疗效
15.Clinical Study on Regimen Cyclophosphamide,Ara-C and Topotecan (CAT) in Treatment of Patients with Refractoryor Relapsed Acute Myelogenous Leukemia环磷酰胺、阿糖胞苷和拓扑替康联合方案治疗难治和复发急性髓系白血病的临床研究
16.Study of Gene Expression Profiles in Refractory Acute Myeloid Leukemia (M2a);难治性急性髓系白血病（M2a）基因表达谱的研究
17.Clinical Research of Modified CAG Regimen for the Treatment of Relapsed Acute Myeloid Leukemia改良CAG方案治疗成人复发性急性髓系白血病的临床研究
18.Aclacinomycin and Ara-c on acute refractory and recurrent leukemia阿克拉霉素与阿糖胞苷联合方案治疗难治及复发性急性白血病
相关短句/例句
Refractory or recurrent acute myelomatosis难治性或复发性急性髓性白血病
3)relapsed/refractory acute myeloid leukemia复发/难治急性髓系白血病
4)refractory and relapsed AML难治复发急性髓系白血病
1.Methods:13 cases(17 times)with refractory and relapsed AML were treated with Fludarabine 30mg/m~2/d and Ara-c 2g/m~2/d for 5 days,and granulocyte colony stimulating factor G-CSF 300μg/d from day 0 till neutrophil recovery(ANC≥1×10~9/L).目的观察FLAG方案(氟达拉滨、阿糖胞苷及粒细胞集落刺激因子组成)治疗难治复发急性髓系白血病的疗效、骨髓抑制时间以及不良反应。
5)Relapsed/refractory acute leukemia难治/复发性急性白血病
6)refractory/relapsed acute myeloid leukemia难治性急性髓性白血病
1.Objective:To investigate the feasibility of FATG regimen (fludarabine, cytarabine, Topotecan + G-CSF) applied as the first line therapy in the adult patients with refractory/relapsed acute myeloid leukemia.方法:对难治性急性髓性白血病(RAML)病人采用FATG方案(氟达拉滨、阿糖胞苷、拓扑替康+G-CSF)化疗,观察疗效及毒副作用。
延伸阅读
性起【性起】 （术语）对缘起之称。缘起者真妄和合而起之诸法，故有染净之差别，是乃因位之如来藏。性起者唯真如法性自起而为诸法，故唯有净法，是乃果海之法身。性起与性具云何分别？答：性起为华严之极谈，性具为天台之圆谈。华严宗不言性具，虽谈真如法性之理，性起万法，然不言彼理性之内具诸法也。指要钞下曰：“他宗极圆，只云性起，不云性具，深可思量。又不谈性具百界，但论变造诸法，何名无作耶？”
